BVF Inc. IL Lowers Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

BVF Inc. IL reduced its stake in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 20.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,771,417 shares of the company's stock after selling 467,569 shares during the period. Structure Therapeutics makes up 1.6% of BVF Inc. IL's investment portfolio, making the stock its 15th biggest position. BVF Inc. IL owned about 3.09% of Structure Therapeutics worth $48,041,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in GPCR. State Street Corp lifted its stake in Structure Therapeutics by 27.0% during the third quarter. State Street Corp now owns 12,295 shares of the company's stock worth $540,000 after purchasing an additional 2,611 shares during the last quarter. Barclays PLC lifted its position in Structure Therapeutics by 64.5% in the 3rd quarter. Barclays PLC now owns 81,138 shares of the company's stock worth $3,562,000 after buying an additional 31,815 shares during the last quarter. Geode Capital Management LLC boosted its stake in Structure Therapeutics by 0.7% in the third quarter. Geode Capital Management LLC now owns 45,225 shares of the company's stock worth $1,985,000 after buying an additional 312 shares in the last quarter. Franklin Resources Inc. grew its position in Structure Therapeutics by 9.4% during the third quarter. Franklin Resources Inc. now owns 706,106 shares of the company's stock valued at $30,991,000 after acquiring an additional 60,397 shares during the last quarter. Finally, Principal Financial Group Inc. raised its stake in shares of Structure Therapeutics by 230.0% during the third quarter. Principal Financial Group Inc. now owns 545,359 shares of the company's stock worth $23,936,000 after acquiring an additional 380,115 shares in the last quarter. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Structure Therapeutics Trading Down 3.2 %

Shares of GPCR stock traded down $0.85 during trading hours on Friday, reaching $25.97. The company's stock had a trading volume of 388,328 shares, compared to its average volume of 924,237. The stock has a market capitalization of $1.49 billion, a P/E ratio of -35.09 and a beta of -1.69. The firm's fifty day simple moving average is $20.87 and its 200 day simple moving average is $27.11. Structure Therapeutics Inc. has a one year low of $13.22 and a one year high of $62.74.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.03). As a group, equities research analysts forecast that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

GPCR has been the topic of several recent research reports. William Blair initiated coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They set an "outperform" rating on the stock. HC Wainwright reiterated a "buy" rating and issued a $80.00 price objective on shares of Structure Therapeutics in a report on Tuesday, April 22nd. Finally, Citigroup assumed coverage on Structure Therapeutics in a report on Friday, May 2nd. They set a "buy" rating and a $60.00 target price for the company. Nine analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $78.63.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.